中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2014年
29期
12-13,14
,共3页
晚期胃癌%脱氧核苷酸注射液%化疗
晚期胃癌%脫氧覈苷痠註射液%化療
만기위암%탈양핵감산주사액%화료
Advanced gastric cancer%Deoxynucleotide injection%Chemotherapy
目的：比较脱氧核苷酸注射液联合化疗与单纯化疗治疗晚期胃癌的临床疗效及不良反应。方法68例晚期胃癌患者采用随机数字表法分为治疗组38例和对照组30例。治疗组采用脱氧核苷酸注射液联合化疗,对照组给予单独化疗。随访21 d评估患者的骨髓抑制、体重改变及免疫功能。结果治疗组7 d后WBC计数为(3.9±1.3)×109/L,血小板计数为(65.2±23.7)×109/L, WBC恢复正常人数占63.2%, III度+ IV度骨髓抑制发生率为10.5%；对照组分别为(3.0±1.2)×109/L、(48.8±21.4)×109/L、33.3%、40.0%,两组比较差异具有统计学意义(P<0.05)。随访14 d, CD3+(62.3±18.7 VS 55.4±16.8), CD4+(39.1±14.2 VS 38.3±5.0), NK细胞(33.5±12.6 VS 24.4±11.2)水平治疗组高于对照组,两组比较差异具有统计学意义(P<0.05)。另外两组治疗21 d后,治疗组肌肉不良事件发生率、肝损伤事件发生率、医院感染发生率、体重增加量、生活质量(KPS)评分提高≥10分分别为10.5%、5.3%、5.3%、(1.9±0.5)kg、65.8%；对照组则分别为50.0%、20.0%、33.3%、(-0.8±0.2)kg、40.0%,两组比较差异具有统计学意义(P<0.05)。结论脱氧核苷酸注射液减轻晚期胃癌化疗后的骨髓抑制,激活免疫功能,提高胃癌患者的体重,改善生存质量。
目的：比較脫氧覈苷痠註射液聯閤化療與單純化療治療晚期胃癌的臨床療效及不良反應。方法68例晚期胃癌患者採用隨機數字錶法分為治療組38例和對照組30例。治療組採用脫氧覈苷痠註射液聯閤化療,對照組給予單獨化療。隨訪21 d評估患者的骨髓抑製、體重改變及免疫功能。結果治療組7 d後WBC計數為(3.9±1.3)×109/L,血小闆計數為(65.2±23.7)×109/L, WBC恢複正常人數佔63.2%, III度+ IV度骨髓抑製髮生率為10.5%；對照組分彆為(3.0±1.2)×109/L、(48.8±21.4)×109/L、33.3%、40.0%,兩組比較差異具有統計學意義(P<0.05)。隨訪14 d, CD3+(62.3±18.7 VS 55.4±16.8), CD4+(39.1±14.2 VS 38.3±5.0), NK細胞(33.5±12.6 VS 24.4±11.2)水平治療組高于對照組,兩組比較差異具有統計學意義(P<0.05)。另外兩組治療21 d後,治療組肌肉不良事件髮生率、肝損傷事件髮生率、醫院感染髮生率、體重增加量、生活質量(KPS)評分提高≥10分分彆為10.5%、5.3%、5.3%、(1.9±0.5)kg、65.8%；對照組則分彆為50.0%、20.0%、33.3%、(-0.8±0.2)kg、40.0%,兩組比較差異具有統計學意義(P<0.05)。結論脫氧覈苷痠註射液減輕晚期胃癌化療後的骨髓抑製,激活免疫功能,提高胃癌患者的體重,改善生存質量。
목적：비교탈양핵감산주사액연합화료여단순화료치료만기위암적림상료효급불량반응。방법68례만기위암환자채용수궤수자표법분위치료조38례화대조조30례。치료조채용탈양핵감산주사액연합화료,대조조급여단독화료。수방21 d평고환자적골수억제、체중개변급면역공능。결과치료조7 d후WBC계수위(3.9±1.3)×109/L,혈소판계수위(65.2±23.7)×109/L, WBC회복정상인수점63.2%, III도+ IV도골수억제발생솔위10.5%；대조조분별위(3.0±1.2)×109/L、(48.8±21.4)×109/L、33.3%、40.0%,량조비교차이구유통계학의의(P<0.05)。수방14 d, CD3+(62.3±18.7 VS 55.4±16.8), CD4+(39.1±14.2 VS 38.3±5.0), NK세포(33.5±12.6 VS 24.4±11.2)수평치료조고우대조조,량조비교차이구유통계학의의(P<0.05)。령외량조치료21 d후,치료조기육불량사건발생솔、간손상사건발생솔、의원감염발생솔、체중증가량、생활질량(KPS)평분제고≥10분분별위10.5%、5.3%、5.3%、(1.9±0.5)kg、65.8%；대조조칙분별위50.0%、20.0%、33.3%、(-0.8±0.2)kg、40.0%,량조비교차이구유통계학의의(P<0.05)。결론탈양핵감산주사액감경만기위암화료후적골수억제,격활면역공능,제고위암환자적체중,개선생존질량。
ObjectiveTo compare the clinical effects and adverse reactions of deoxynucleotide injection combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric cancer.Methods A total of 68 cases of advanced gastric cancer were randomly divided into treatment group (n=38) and control group (n=30). The treatment group was treated by deoxynucleotide injection combined with chemotherapy. The control group received chemotherapy alone. After 21d of follow-up, assessments of the patient's bone marrow suppression, weight change, and immune function were made.ResultsThe WBC count of treatment group after 7d was (3.9±1.3)×109/L, platelet count was (65.2±23.7)×109/L, WBC normal persons accounted for 63.2%, the III+IV myelosuppression rate was 10.5%. These indexes of the control group were (3.0±1.2)×109/L, (48.8±21.4)×109/L, 33.3%, 40.0%. Differences between the two groups had statistical significance (P<0.05). After follow-up for 14 d, levels of CD3+(62.3±18.7 VS 55.4±16.8), CD4+(39.1±14.2 VS 38.3±5.0), NK cells (33.5±12.6 VS 24.4±11.2) in the treatment group were higher than those of the control group, and the differences between the two groups were statistically significant (P<0.05). After 21d of treatment, muscles incidence of adverse events, the incidence of liver damage event, the incidence of nosocomial infections, weight gain, Karnofsky performance score (KPS) improved ≥ 10 points were 10.5%, 5.3%, 5.3%, (1.9±0.5)kg, 65.8% in the treatment group, and those of the control group were 50.0%, 20.0%, 33.3%, (-0.8±0.2)kg, 40.0%. The differences between the two groups were statistically significant (P<0.05).ConclusionDeoxynucleotide injection in advanced gastric cancer after chemotherapy can reduce bone marrow suppression, activation of the immune function, and improve gastric cancer patient's weight and life quality.
